Signatur Biosciences Analysis: $500K Raised
What is Signatur Biosciences?
Signatur Biosciences develops PCRchitectur, a molecular intelligence platform that expands traditional qPCR for multiplexed gene-signature testing. The company says its system combines competitive PCR biology with machine learning and works on existing qPCR instruments using off-the-shelf reagents. It is developing OncoSignatur Breast, a decentralized breast cancer prognostic test kit, and states the technology is not for sale yet.
Location
London, United Kingdom
Employees
11-50
Founded
2022
Product Features & Capabilities
- Smart PCR kits for detecting complex diseases, integration with standard qPCR machines, ability to analyze multiple RNA biomarkers, simplified workflows for precision diagnostics, technology designed for existing clinical infrastructure.
How much Signatur Biosciences raised
s: - $500,000
August 22, 2022Lead Investor: Y Combinator
Who are the founders of Signatur Biosciences
JG
John Goertz
Co-founder, CSO
CD
Celestin de Wergifosse
Co-founder, CEO
Market Focus
Signatur Biosciences primarily focuses on the biotechnology industry, specifically in the development of diagnostic tools for complex diseases through innovative PCR (Polymerase Chain Reaction) kits that detect gene expression signatures.
Investors
- Myelin VC
- PSR Crypto
- Riceberg Ventures
- Imperial College London
Competitors Overview
The main competitors of Signatur Biosciences in the PCR kits and gene expression diagnostics market include:
-
Roche Diagnostics: A leading player in molecular diagnostics, Roche offers a comprehensive range of PCR systems and has a strong distribution network. Their focus on strategic acquisitions enhances their market position.
-
Abbott Laboratories: Known for its innovative diagnostic solutions, Abbott provides a variety of PCR-based tests, particularly in point-of-care settings, which may offer faster results compared to traditional methods.
-
Thermo Fisher Scientific: This company is recognized for its rapid PCR testing platforms and extensive product portfolio, which includes reagents and instruments for molecular diagnostics.
-
Danaher Corporation: Danaher is noted for its continuous product development and robust R&D initiatives, making it a formidable competitor in the diagnostics space.
-
QIAGEN: Specializing in molecular testing products, QIAGEN offers a range of solutions for PCR and gene expression analysis, focusing on high-quality reagents and kits.
-
Illumina: While primarily known for sequencing technologies, Illumina also competes in the PCR market with a strong emphasis on product innovation and geographic expansion.
Notable differences or advantages of these competitors include their established market presence, extensive product offerings, and significant investment in research and development, which may provide them with a competitive edge over Signatur Biosciences.
See something that needs updating? Suggest edits to this profile.